OCT 05, 2018 09:00 AM PDT

FDA approves a new drug for an advanced type of skin cancer

As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. Anticancer immunotherapy drugs are one class of drugs that have been developed recently and that have successfully helped in treating different types of cancers, no wonder that the Nobel prize in medicine/physiology this year has been awarded to the two doctors who contributed in discovering this class. 

Using PD-1/PD-L1 against cancer in immunotherapy, Credit: abcam

Recently the U.S. Food and Drug Administration has approved a new drug called Libtayo (cemiplimab-rwlc) which is a member of the anticancer immunotherapy class of drugs, it is an injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who cannot be treated with surgery or radiation.

This drug is the first and only drug to treat this type of skin cancer (CSCC) which is the second most common type of cancer in the United States and represents 20% of all non-melanoma skin cancer. It is usually developed by regular exposure to the sun or ultraviolet radiation. It can cause disfigurement and other local complications as bleeding or infection. Also, it can metastasize to other organs in the body which can make it life-threatening.

Libtayo works by blocking the PD-1 / PD-L1 pathway, by doing this it can help the immune system fights cancer.

The PD-1 is a protein receptor expressed on T-cells, it binds to its ligand PD-L1 which is commonly expressed on macrophages and dendritic cells. They both belong to the family of checkpoints that function to ensure that the immune system only reacts at the right time.

Cancer cells express a PD-L1 receptor that after binding to PD-1, this inhibits T cells making them unable to destroy the cancer cells and they keep on growing.

Two open-label clinical trials were done to study the efficacy and safety of Libtayo with 108 patients included (75 with metastatic disease and 33 with the locally-advanced disease). The results showed that the tumors shrunk or disappeared in 47.2% of all patients treated.

Libtayo side effects include fatigue, rash, and diarrhea. It can also cause severe or life-threatening side effects due to its effect on normal tissues and organs that can impair their functions, like lung problems (pneumonitis), intestinal problems (colitis), liver problems (hepatitis), hormone gland problems (endocrinopathies), skin (dermatologic) problems and kidney problems. Patients should also be monitored for infusion-related reactions.

It is not safe in pregnancy as it can cause harm to the fetus.

“We are continuing to see a shift in oncology toward identifying and developing drugs aimed at a specific molecular target. With the Libtayo approval, the FDA has approved six immune checkpoint inhibitors targeting the PD-1 / PD-L1 pathway for treating a variety of tumors, from bladder to head and neck cancer, and now advanced CSCC,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This type of cancer can be difficult to treat effectively when it is advanced, and it is important that we continue to bring new treatment options to patients.”

Watch the video below to learn more about cancer immunotherapy.

Source: FDA, abcam

About the Author
  • A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
AUG 07, 2018
AUG 07, 2018
Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?
A group of US researchers have identified CD13 in certain subtypes of B-cell neoplasms, thereby aiding in a more detailed diagnosis....
OCT 04, 2018
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
OCT 06, 2018
Drug Discovery
OCT 06, 2018
New Class of Drugs for Breast Cancer Therapy
Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively be...
NOV 02, 2018
Cell & Molecular Biology
NOV 02, 2018
Natural Molecule Enables Obese Mice to Shed Weight
A molecule that has been a focus of cancer research has been found to be a significant regulator of metabolism....
NOV 05, 2018
Cell & Molecular Biology
NOV 05, 2018
Using Imaging to Understand Cancer Growth
Most types of cells in our body go through a critical renewal process in which cells divide into two new ones. But it can get out of control as well....
Loading Comments...